View Cancer Clinical Trials
Utility of Early Versus Late Androgen Deprivation in Prostate Cancer Patients with Biochemical Relapse
- To measure the utility of treatment versus observation in patients with rising PSA
- All patients with rising PSA after definitive treatment of their prostate cancer with no evidence of metastatic disease are eligible for this study.
- The patient population includes patients with biochemical failure who are being followed at Taussig Cancer Institute or at Glickman clinics.
- The patient will be informed that their choice of whether to participate or not will have no influence on their medical care.
Exclusion Criteria Not Available
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.